ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / NKTX / news
EQ (31) HURA (32) NERV (31) OKUR (34) ⌘ Pro Terminal →

Why NKTX Stock dropped -2.56% Today — RQD Quant Desk Flash

$1.52 -2.56% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.51

Nkarta Inc. (NKTX) carries a Roarable Rating of E (Strong Sell) with 26/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $108.9M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on NKTX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is NKTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Nkarta Inc. (NASDAQ: NKTX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 26/100 at a spot price of $1.52 (-2.56% 1D, market cap $108.9M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 7/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, NKTX ranks #908 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does NKTX compare to EQ and HURA in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NKTX carries a Roarable E (26/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, EQ (Equillium Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $108.1M) and HURA (TuHURA Biosciences Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $109.6M). Among the 5-stock peer group, NKTX leads on earnings multiple (N/A) while NKTX leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for NKTX?
▼

Per NKTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001787400), Nkarta Inc. generated $341.6M in revenue (-4.8% YoY), -$104.1M in net income, and -$89.9M in free cash flow against $404.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.51 (-0.65%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (26/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.5% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510026
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D-
Cash (4)Whales (3)SEC (7)Macro (7)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-14.5% Base Target
$4 Bull$1 Base$1 Bear
📬 FREE NKTX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NKTX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (26/100 Composite)
🔍 WHY NKTX SCORES 26/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+7/20 pts (27% of score)

Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 3/9

▲ #2 Bullish Driver: Macro Regime Fit+7/20 pts (27% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 24.3 (OVERSOLD (<32))

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
34
Grade E$2.03-13.8% Next Q
Q2 (-2Q)
31
Grade E$1.75-1.7% Next Q
Q3 (-1Q)
29
Grade E$1.72-11.6% Next Q
Current
26
Grade E$1.52-10.5% Hist 90D α
Trajectory: E (34) → E (26)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a NKTX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While NKTX currently carries a cautious 26/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.38) and Max Pain ($1.60) forces dealer call-delta covering toward $3.91.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NKTX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “NKTX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 26%NO 74%Trade / Inspect Odds →
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why NKTX Stock dropped -2.56% Today — RQD Quant Desk Flash

Nkarta Inc. (NKTX) dropped -2.56% to $1.52, trading at 2% of its 52-week range ($1.48 – $3.72). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

  • ▸Technical Tape: Trading at 2% of its 52-week range ($1.48 – $3.72) with RSI-14 at 24.3 (OVERSOLD (<32)).
  • ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $1.52 (no active unusual options sweep snapshot on file).
  • ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live NKTX Headlines & Catalysts
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NKTX)

  • ✓Walkthrough of NKTX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
NKTX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -50.65%🛡️ HOLDING TREND SUPPORT
2026-11-04O $1.56H $1.56L $1.52C $1.52VOL 1.39M
RES: $2.89SUP: $1.46SMA50: $2.38SMA200: $2.53
$3.88$3.23$2.58$1.93$1.28RES $2.89SUP $1.46$1.522026-05-052026-06-182026-08-052026-09-212026-11-04
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NKTX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NKTX Butterfly Map → + Track NKTX →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -4.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on NKTX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NKTX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for NKTX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NKTX)

Health Care Rank #908 of 1015 ⚔️ EQ vs NKTX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NKTX vs. EQ, HURA, NERV, OKUR)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Nkarta Inc. (NKTX) ranks #908 by composite RQD confidence (26/100, grade E) and #638 by equity capitalization ($108.9M). Within this direct 5-issuer industry benchmark cohort, NKTX leads on earnings valuation at N/A trailing P/E, while NKTX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. OKUR currently holds the highest overall quantitative score in the immediate peer group at 34/100 (E) compared with NKTX at 26/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
NKTX ACTIVE
Nkarta Inc.
E 26/100 — — -35.0% -2.56% $108.9M Benchmark Subject
EQ
Equillium Inc.
E 31/100 — — -35.0% +0.73% $108.1M /eq-vs-nktx →
HURA
TuHURA Biosciences Inc.
E 32/100 — — -35.0% -10.88% $109.6M /hura-vs-nktx →
NERV
Minerva Neurosciences Inc
E 31/100 — — -35.0% +1.08% $112.0M /nerv-vs-nktx →
OKUR
OnKure Therapeutics Inc. (Class A)
E 34/100 — — -35.0% -1.14% $104.9M /okur-vs-nktx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001787400 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Nkarta Inc. (NKTX) reported GAAP revenue of $341.6M (-4.8% vs. FY2024 revenue of $358.9M , and -7.3% cumulative change since FY2023) , GAAP net income of -$104.1M, operating cash flow of -$88.7M, and free cash flow of -$89.9M (+13.6% YoY). On the balance sheet, NKTX closed FY2025 with $404.2M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $341.6M -$104.1M -$88.7M -$89.9M $404.2M —
FY2024 (FY) 2024-12-31 $358.9M -$108.8M -$99.7M -$104.1M $501.2M —
FY2023 (FY) 2023-12-31 $368.6M -$117.5M -$86.2M -$86.2M — —

3. NKTX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NKTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Nkarta Inc. (NASDAQ: NKTX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 26/100 at a spot price of $1.52 (-2.56% 1D, market cap $108.9M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 7/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, NKTX ranks #908 in composite RQD confidence.

How does NKTX compare to EQ and HURA in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NKTX carries a Roarable E (26/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, EQ (Equillium Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $108.1M) and HURA (TuHURA Biosciences Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $109.6M). Among the 5-stock peer group, NKTX leads on earnings multiple (N/A) while NKTX leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for NKTX?

Per NKTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001787400), Nkarta Inc. generated $341.6M in revenue (-4.8% YoY), -$104.1M in net income, and -$89.9M in free cash flow against $404.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is NKTX trading relative to its 50-day, 200-day, and 52-week technical levels?

NKTX last traded at $1.52 (-2.56% on volume of 1,394,464 shares), positioning the stock -36.13% below its 50-day simple moving average ($2.38) and -39.92% below its 200-day simple moving average ($2.53). Across its 52-week range of $1.48 to $3.72, NKTX sits at the 1.8% percentile with a 14-day RSI of 24.3 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.33 to $1.71).

Direct Sub-Reports: NKTX RQD Cockpit NKTX 12M Forecast NKTX Earnings & Move NKTX Dividends & DRIP NKTX Insiders & 13F NKTX Whale Options NKTX Profit Sankey NKTX News & Why
ROARABLE RATING BRIEF • RQD 26/100 (E) ✓ SEC XBRL & RQD VERIFIED

NKTX — Nkarta Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Nkarta Inc. (NKTX) earns a live Roarable RQD composite score of 26/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.52 (-2.56% 1D, market capitalization $108.9M).

  • Fundamental Cash Engine (4/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (7/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Nkarta Inc. (NKTX) is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Pharmaceutical Preparations industry..1B. — describes its specific products, customers, or revenue model beyond the sector and industry classification. The reported revenue for the periods provided is —.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Nkarta Inc. (NKTX) reported $341.6M in annual revenue (up from $358.9M in FY2024, -4.8% YoY) and -$104.1M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($368.6M revenue, -$117.5M net income) through FY2025, NKTX scaled operating cash flow to -$88.7M and free cash flow to -$89.9M, backed by $404.2M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 26/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 4/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.48 – $3.72 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), NKTX carries a macro regime beta of 1.00 and gross margin of —.

  • Key Question #1: Can NKTX sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $341.6M and free cash flow of -$89.9M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is NKTX's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

NKTX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Nkarta Inc. (NKTX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to NKTX Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

NKTX Bull vs. Bear Conversation Board — What's Your Call at $1.52?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NKTX 🐻 33% BEARISH CONVICTION
1. Pick Your Side on NKTX:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $1.84 (+17.9%)
📌 Pinned Debate

A recent H.C. Wainwright initiation with a buy rating is cited in the news wire, though the source provides no price target or supporti

Here is why I am bullish on NKTX here at $1.56: A recent H.C. Wainwright initiation with a buy rating is cited in the news wire, though the source provides no price target or supporting detail.. Compare NKTX's 0.0% operating margin and -35.0% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $1.48 are getting bought.

VolSurface_Trader 🐂 BULL

Both sides have a point here — NKTX's 7/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

CR CreditSpread_Watch RQD DEBATE OPENER • Balance Sheet Analyst 🐻 BEARISH 🎯 Target: $1.26 (-19.2%)
Spot @ $1.56

The RQD rating of 31 (grade E) reflects zero revenue, -35% ROIC, zero free cash flow yield, and an Altman Z-Score of 0.2.

Careful chasing NKTX at $1.56. The RQD rating of 31 (grade E) reflects zero revenue, -35% ROIC, zero free cash flow yield, and an Altman Z-Score of 0.2.. Gross margin is 0.0%, but operating margin is 0.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $1.26 on multiple compression.

LIVE TAPE